Partell Specialty Pharmacy Recalls Estradiol Pellets Due to Sterility Concerns
Partell Specialty Pharmacy is recalling Estradiol 50 mg pellets in Nevada due to a non-approved sterilization method.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric for drug recalls involving potential health risks.
Plain-English summary
Partell Specialty Pharmacy is recalling Estradiol 50 mg (SD) pellets in amber vials. The recall is being conducted because the firm used a non-approved method of sterilization for these drug products.
The affected product is prescription-only and was distributed in Nevada. The specific lot number is 20171009@49, with a beyond-use date of 04/07/2018.
Consumers who have this product should stop using it and contact their healthcare provider or the pharmacy for further instructions.
The recalled product
- Product
- Estradiol 50 mg (SD) pellets in amber vial, Rx only, Partell Specialty Pharmacy, 5835 S. Eastern Ave. #101, Las Vegas, NV 89119 (702) 791-3800.
- Manufacturer
- Partell Specialty Pharmacy
- Category
- Drug — Prescription Steroids
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: 20171009@49
- BUD 04/07/2018.
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 49 recalled by Partell Specialty Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 49 products in this recall →Related recalls
Same manufacturer · Partell Specialty Pharmacy
See all →- SeverePartell Specialty Pharmacy Recalls Glutathione Vials Due to Sterility Concerns
FDA (Drugs) · 2018-04-25
- SeverePartell Specialty Pharmacy Recalls Nandrolone Decanoate Due to Sterility Concerns
FDA (Drugs) · 2018-04-25
- HighPartell Specialty Pharmacy Recalls Estradiol Pellets Due to Sterility Concerns
FDA (Drugs) · 2018-04-25
- SeverePartell Specialty Pharmacy Recalls Testosterone Pellets Due to Sterility Concerns
FDA (Drugs) · 2018-04-25
- SeverePartell Specialty Pharmacy Recalls Ascorbic Acid Vials Due to Sterility Concerns
FDA (Drugs) · 2018-04-25
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereFDA Recalls Estradiol Pellets Due to Lack of Sterility Assurance
FDA (Drugs) · 2015-11-04
- SevereFDA Recalls Estradiol Pellets Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-11-04
- SevereEstradiol Pellets Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2015-09-23
- SevereEstradiol Valerate Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2016-06-15
- SevereMoses Lake Pharmacy Recalls Estradiol Pellets Due to Sterility Concerns
FDA (Drugs) · 2015-11-04
- CriticalPhysician Preferred Medical Recalls Epel 18 mg Estradiol Pellets Due to Sterility Failure
FDA (Drugs) · 2015-05-13